Teni Boulikas, Ph.D., is the Founder, Chairman of the Board and CEO, of Regulon, Inc. based in California, USA and Athens, Greece. Regulon is an oncology-focused drug delivery company leveraging proprietary and differentiated tumor-targeting nanotechnology to develop improved branded versions of leading chemotherapy drugs. Regulon’s lead product, Lipoplatin, is a liposomal encapsulation of cisplatin, the most widely-used chemotherapy drug with applications to over 50% of human malignancies. Lipoplatin nanoparticles, loaded with cisplatin are uptaken by tumors and metastases (up to 200-fold higher than normal tissue) by leaking through the compromised endothelium of tumor vasculature (extravasation) and by the avidity of tumors for nutrients with Lipoplatin disguised as a nutrient with its lipid shell. Moreover, Lipoplatin nanoparticles fuse with the cell membrane to empty its toxic payload inside the cell. Published Phase III studies show a lower toxicity with improved therapeutic index in adenocarcinomas of the lungs compared to cisplatin; this feature was not shown by other platinum blockbuster drugs (carboplatin, oxaliplatin) and it is for the first time in Europe cisplatin will be replaced by Lipoplatin in lung adenocarcinams (since 70s).
Teni Boulikas is not only the inventor of Lipoplatin, but in addition he orchestrated all stages of preclinical and clinical development of this drug including testing through Phase I, II and III human trials. Teni is also in charge of the regulatory team and has filed to European Medicines Agency (EMA) for marketing authorization (under the name Nanoplatin) for NSCLC and as first-line against pancreatic cancer. Teni is also the inventor of Lipoxal (liposomal oxaliplatin, Phase II for colorectal cancer), LipoVIL12 (a liposomal virus expressing the human IL-12 gene, Phase II planned against metastatic melanoma), Liporubicin (liposomal doxorubicin able to fuse with the membrane of the tumor cell, currently at preclinical stage), liposomal paclitaxel and of numerous 4th generation liposomal drugs and liposomal peptides.
Teni holds a B.Sc. degree in Chemistry from the Aristotelian University of Thessaloniki. He received his Ph.D. from the Southwestern Medical School in Dallas, Texas in Biochemistry. As a European Molecular Biology Organization (EMBO) postdoctoral Fellow for 2 years Teni studied nuclear matrix-chromatin interaction at the Swiss Institute for Experimental Cancer Research in Epalinges sur Lausanne for from 1979-1984. He then became Assistant Professor of Biochemistry and Head of the Laboratory of Monoclonal Antibodies at the University of Sherbrooke in Quebec with research activities on cloning methods, immunoglobulin genes, and monoclonal antibodies. Teni Boulikas moved to the Linus Pauling Institute in Palo Alto in 1988 as an Investigator and Director of the Laboratory of Molecular Carcinogenesis and later at the Institute of Molecular Medical Sciences (Palo Alto). He has over 80 publications.
In 1997 Teni founded Regulon in Palo Alto and then Mountain View, California and Regulon AE as a service provider in Athens, Greece in 2001 with research activities focusing on liposomal encapsulation of drugs. In 2003 he received a world patent on encapsulation of cisplatin, other structurally unrelated drugs and genes that formed the platform technology of Regulon. Teni Boulikas is the organizer of 8 International Conferences aiming at bridging the fields of Gene Therapy and Molecular Biology & Medicine, and Founder of the International Society of Gene Therapy and Molecular Biology. He has also the responsibility of managing patient data, promoting the clinical trials of Regulon in several countries and assembling the most exciting teams of oncologists as Regulon’s collaborators. Teni is the Editor of “Cancer Therapy” and “Gene Therapy and Molecular Biology” that can be accessed freely on the web sites www.Cancer-Therapy.org and www.gtmb.org. This is a free service to the scientific community to promote science and cancer treatments. Long-standing interests of Teni are in the field of natural products and their use to promote human health and as a preventive medicine. He has formulated ointments and creams based on plant extracts against burns and many other skin conditions.